Amedisys Inc (NASDAQ:AMED) insider David B. Pearce sold 1,000 shares of the business’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the sale, the insider now directly owns 10,488 shares of the company’s stock, valued at $524,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Shares of Amedisys Inc (AMED) traded down 2.10% during midday trading on Wednesday, reaching $48.46. 308,022 shares of the company’s stock were exchanged. The stock has a market capitalization of $1.64 billion, a P/E ratio of 41.42 and a beta of 0.89. Amedisys Inc has a 12-month low of $34.58 and a 12-month high of $65.91. The firm has a 50-day moving average of $58.14 and a 200-day moving average of $54.09.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.12. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The company had revenue of $378.80 million during the quarter, compared to analysts’ expectations of $380.80 million. During the same period last year, the company posted $0.42 EPS. Amedisys’s revenue was up 5.0% on a year-over-year basis. Analysts anticipate that Amedisys Inc will post $2.21 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “David B. Pearce Sells 1,000 Shares of Amedisys Inc (AMED) Stock” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/09/david-b-pearce-sells-1000-shares-of-amedisys-inc-amed-stock.html.

AMED has been the subject of several recent research reports. Zacks Investment Research downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a research report on Tuesday, May 2nd. Jefferies Group LLC reissued a “buy” rating and set a $57.00 target price on shares of Amedisys in a research report on Friday, April 28th. Mizuho raised shares of Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 target price for the company in a research report on Wednesday, May 3rd. Royal Bank Of Canada reissued a “hold” rating and set a $56.00 target price on shares of Amedisys in a research report on Monday, June 5th. Finally, Stephens boosted their target price on shares of Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 4th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $56.50.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. boosted its position in shares of Amedisys by 2,877.7% in the first quarter. BlackRock Inc. now owns 5,676,870 shares of the health services provider’s stock valued at $290,032,000 after buying an additional 5,486,225 shares during the period. Vanguard Group Inc. boosted its position in shares of Amedisys by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,369,678 shares of the health services provider’s stock valued at $121,067,000 after buying an additional 63,238 shares during the period. FMR LLC boosted its position in shares of Amedisys by 6.9% in the first quarter. FMR LLC now owns 2,352,632 shares of the health services provider’s stock valued at $120,196,000 after buying an additional 152,632 shares during the period. William Blair Investment Management LLC boosted its position in shares of Amedisys by 8.1% in the first quarter. William Blair Investment Management LLC now owns 1,632,242 shares of the health services provider’s stock valued at $83,391,000 after buying an additional 122,305 shares during the period. Finally, American Century Companies Inc. boosted its position in shares of Amedisys by 148.7% in the first quarter. American Century Companies Inc. now owns 1,200,754 shares of the health services provider’s stock valued at $61,347,000 after buying an additional 717,939 shares during the period. 99.80% of the stock is owned by institutional investors.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.